Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Computacenter appoints Keith Mortimer as new CFO

(Sharecast News) - B2B tech firm Computacenter has promoted its head of group commercial finance to the chief financial officer position following a nine-month internal and external search. Keith Mortimer, who has been with the company since 1999 and has held various senior finance and commercial roles, will be appointed CFO on 1 September, some nine months after the exit of former CFO Christian Jehle who stepped down at the end of 2024 by mutual agreement.

Mortimer, a chartered accountant, is said to have played a big part in developing how Computacenter financially forecasts and manages the business, and govern contracts through their lifecycle.

He will be given an annual base salary of £390,000 and be eligible for a bonus award of 150% of salary, half of which will be deferred into shares.

"I look forward to working even more closely with Keith, as he takes up the position of chief financial officer," said chief executive Mike Norris.

"His detailed knowledge of the business from end to end will be invaluable in helping us achieve our growth ambitions for the business, particularly as we continue to make significant investment in our systems, tools and processes to enhance both our operating efficiency and the customer experience".

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.